Postorgasmic Illness Syndrome Research Articles

Nonsteroidal anti‐inflammatory drugs are effective against postorgasmic illness syndrome: A case report

Nonsteroidal anti‐inflammatory drugs are effective against postorgasmic illness syndrome: A case report

Clinical experience with post-orgasmic illness syndrome (POIS) patients-characteristics and possible treatment modality.

Post-orgasmic illness syndrome (POIS) is a rare condition that includes a cluster of post-ejaculatory symptoms with debilitating physical and psychological consequences. The prevalence and incidence of POIS remain unknown as well as the pathophysiology of the syndrome, and there are no well-studied recognized treatment modalities. The current retrospective observational study describes a series of 14 highly selected patients who were actively looking for medical help as POIS has a significant effect on patients and their partners. The aim is to increase knowledge about this syndrome and possible treatment modality. According to a standard protocol, patients have been systematically interviewed, had a physical examination, laboratory blood tests, and treatments. Mean age was 34.07 ± 6.65 years. The majority of patients had only one symptom in common-extreme fatigue. The most prevalent complaints were head pressure/heaviness, nose congestion and muscle tension; all patients suffered from more than 1 symptom. POIS started on average within 30 min of ejaculation and lasted for 3.5 days. The patients reported emotional and psychosocial burden of their symptoms, which also influence their partner and relationships. Immunoglobulin-E measurements did not show elevated levels and/or significant increase within 24 h after ejaculation. Silodosin, a highly selective alpha1A-blocker, which actually causes anejaculation, was effective treatment in 57% of the patients.

MP84-19 CHARACTERIZING THE DISEASE COURSE AND CURRENT TREATMENT PRACTICES OF POST-ORGASMIC ILLNESS SYNDROME IN A LARGE SAMPLE OF PATIENTS

INTRODUCTION AND OBJECTIVE:Post-orgasmic illness syndrome (POIS) is a rare disorder with debilitating physical and psychological sequela. We characterized the epidemiology, symptomatology, disease ...

139 Characterizing the Epidemiological Landscape of Post-Orgasmic Illness Syndrome

There is paucity of data concerning post-orgasmic illness syndrome (POIS), a rare disorder with debilitating physical and psychological sequela. Given the rarity, and the sensitive and potentially embarrassing symptoms of POIS, this disease remains underdiagnosed and understudied. We sought to characterize the epidemiology of this disease in the hopes of creating a framework for designing a disease-specific questionnaire and helping guide therapeutic investigation. To gather data about the symptomatology, disease course, comorbid conditions, precipitating factors, associated behavioral changes, prevalent treatments and basic demographic data within an online community of patients suffering from POIS. An encrypted survey instrument was designed to be administered to the only known online community for patients suffering from POIS. The survey characterizes the condition using the five diagnostic criteria described previously. The survey questions also allow stratification of the cases into one or more of the seven symptom clusters described in the same study. Respondents were queried on disease course, comorbid conditions, behaviors and demographics.

Introduction: Rare and unusual andrologic syndromes that clinicians should be aware of

There are conditions that are rare and that most providers are unaware of or conditions that consist of a series of symptoms for which there is no agreement that they are even a medical condition. These include painful nocturnal erections, post-orgasmic illness syndrome, body dysmorphic disorder, and post-finasteride syndrome. While some have a psychiatric basis, others clearly have an organic pathophysiology, while for others, there remains much controversy. This month's Views and Reviews will inform the reader of these conditions so they may recognize affected patients and direct them towards appropriate resources for their care.

144 Post-Orgasmic Illness Syndrome: A Case Report and Literature Review with Contemporary Treatment Considerations

144 Post-Orgasmic Illness Syndrome: A Case Report and Literature Review with Contemporary Treatment Considerations

Immunophenotypical Characterization of a Brazilian POIS (Post-Orgasmic Illness Syndrome) Patient: Adding More Pieces to Puzzle

Post-orgasmic illness syndrome (POIS) is a rare condition characterized by post-ejaculatory symptoms. Here is reported the first Brazilian POIS patient. Immunological investigation did not confirm the previous hypothesis of a hypersensitivity reaction. Cell immunophenotyping comparing healthy individuals produced evidence of abnormalities not associated to clinical manifestations. The patient was submitted to specific immunotherapy with transient clinical response and was referred to a psychologist but did not demonstrate clinical improvement of symptoms. Therefore, etiology of POIS remains unclear.

Post orgasmic illness syndrome: what do we know till now?

BackgroundPeri orgasmic dysfunctions are very rare and little information exists on their diagnosis and treatment. One of these conditions is post-orgasmic illness syndrome (POIS), manifesting by a debilitating cluster of symptoms affecting men within seconds, minutes, or hours after ejaculation. The aim of this article is to do a thorough literature review about POIS, in order to elucidate the pathophysiology, the diagnosis and the management of this rare disease.ResultsUpdated literature review on Pubmed was done, using the following terms: “orgasm illness”, “post-orgasmic” and “postorgasmic illness syndrome”. The references of the 17 identified publications were also reviewed for additional 8 relevant articles that were all included in the results.POIS has 5 preliminary diagnostic criteria and criterion 1 has 7 described clusters. Pathophysiological hypotheses include: immunological phenomenon (most relevant), opioid-like withdrawal, neuroendocrine response, transient deregulation of the autonomic nervous system, hypersensitivity and disordered cytokines. Differential diagnoses include: chronic prostatitis, orgasmolepsy, benign orgasmic cephalgia, sneezing and rhinorrhea, postcoital dysphoria, post-coital asthma and rhinitis. Patients have been symptomatically treated with antihistamines, non-steroidal anti-inflammatory drugs, selective serotonin reuptake inhibitors, and benzodiazepines. A trial of hyposensitization therapy with autologous semen was successful.ConclusionPOIS is a rare condition that is underdiagnosed, most probably because of its unclear pathophysiology leading to a lack of treatment options. Further studies are warranted to investigate the prevalence, pathophysiology, and management of this debilitating condition.

Editorial Comment on “First assessment of the validity of the only diagnostic criteria for postorgasmic illness syndrome (POIS)”

Editorial Comment on “First assessment of the validity of the only diagnostic criteria for postorgasmic illness syndrome (POIS)”

First assessment of the validity of the only diagnostic criteria for postorgasmic illness syndrome (POIS).

Postorgasmic illness syndrome (POIS) is a rare condition that affects men and about which little is known. According to Waldinger and colleagues, men with POIS fulfill three or more of five preliminary diagnostic criteria regarding symptoms, time to onset, setting, duration, and spontaneous disappearance. We conducted a self-report study to assess, for the first time, the validity of these criteria. One hundred and twenty-seven men with self-reported POIS have completed the survey, making this the largest study of such men to date. Almost all respondents fulfill a majority of the criteria for POIS; a large minority fulfills all five criteria. Almost all respondents always experience symptoms after ejaculating in at least one ejaculatory setting (sex, masturbation, or nocturnal emission), though only a small majority fulfill the criterion that symptoms occur after all ejaculations because a large minority always experience symptoms in one setting but not always in another. The most common symptom cluster from the criteria, involving fatigue, irritation, and concentration difficulties, is always experienced by 80% of respondents. Median symptom severity is 8 on a 0-10 scale. While almost all men with POIS fulfill a majority of the preliminary diagnostic criteria, there is room for refining some of the criteria.

What Do We Really Know About Intralymphatic Immunotherapy?

Allergen-specific immunotherapy (AIT) is the only causal treatment method of IgE-mediated allergies that may lead to long-term symptom amelioration even after the end of treatment, positively interfere with the course of disease, and improve the immunological situation of the patient. While AIT in general requires treatment periods over 3 up to 5 years, intralymphatic immunotherapy (ILIT) needs only three ultrasound-guided injections of low allergen doses into inguinal lymph nodes with 4-week time interval making the entire treatment possible within 2 months. The number of published ILIT trials is continuously increasing and it has been mainly used for the indication of allergic rhinitis using commercially available grass pollen and birch extracts and Dermatophagoides farinae, Dermatophagoides pteronyssinus, dog or cat allergens, and moreover a recombinant MAT-Fel d 1 vaccine and autologous semen from a patient with post-orgasmic illness syndrome. ILIT is a very promising AIT technique that could widely improve patient treatment However, there is not enough convincing evidence for a routine use of ILIT and no authorized commercial allergen extracts exist for this approach, so far. Dose-escalation studies and prospective DBPC efficacy trials need to be performed in diverse allergens like insect venom. Moreover, pediatric populations have not been present in former ILIT studies.

Postorgasmic Illness Syndrome: What do we know so far?

Postorgasmic Illness Syndrome: What do we know so far?

Intralymphatic Immunotherapy With Autologous Semen in a Korean Man With Post-Orgasmic Illness Syndrome.

Post-orgasmic illness syndrome (POIS) is a very rare disease characterized by local allergic symptoms and transient flu-like illness that nearly always occur after masturbation, coitus, or spontaneous ejaculation and last for 2 to 7 days. In a previous case report, 2 patients with POIS received hyposensitization therapy composed of multiple subcutaneous injections of autologous semen that resulted in a gradual decrease of symptoms. However, this procedure requires patients to endure pain and discomfort during frequent subcutaneous injections and preceding masturbations to obtain the autologous semen used for therapy. Recent studies have suggested that intralymphatic immunotherapy is a promising new method of allergen-specific immunotherapy against allergic diseases, showing a faster onset and longer duration of therapeutic effects after only several intralymphatic injections. We report on a case of a Korean man with POIS who received intralymphatic immunotherapy that alleviated POIS-related symptoms and in whom the existence of semen-specific immunoglobulin E was confirmed using immunoglobulin E immunoblotting and enzyme-linked immunosorbent assay.Kim TB, Shim YS, Lee, SM, et al. Intralymphatic Immunotherapy With Autologous Semen in a Korean Man With Post-Orgasmic Illness Syndrome. Sex Med 2018;6:174–179.

Post-Orgasmic Illness Syndrome: A Review

Post-orgasmic illness syndrome (POIS) is a rare but debilitating cluster of postejaculatory symptoms affecting men. It is a chronic disorder manifesting as a constellation of flulike and allergic symptoms within seconds, minutes, or hours after ejaculation. POIS can be followed by mental sequelae such as diminished concentration and irritability. POIS negatively affects the life of patients by limiting sexual encounters, dampening romantic prospects, creating internal struggles to avoid eroticism, and affecting patients' schedules. First described in 2002, the prevalence and incidence of POIS are still unknown owing to a paucity of studies but is likely under-reported. There are approximately 50 cases of POIS in the literature. Despite the debilitating effects of POIS, the pathophysiology of POIS is still not well elucidated. To provide an update on the current literature on POIS, provide updated information on the pathophysiology of POIS, and discuss potential management options. Comprehensive review of literature pertaining to POIS. The symptoms, classification, pathophysiology, diagnostic considerations, and management of POIS were reviewed. There are 5 preliminary diagnostic criteria for diagnosing this condition. POIS is categorized as primary or secondary. The autoimmune-allergy hypothesis is the most accepted hypothesis explaining the pathogenesis of POIS. A competing hypothesis involves a disorder involving endogenous μ-opioid receptors. Another hypothesis invokes impairment of the cytokine and neuroendocrine responses. There are no known treatment modalities for POIS; patients have been symptomatically treated with antihistamines, selective serotonin reuptake inhibitors, and benzodiazepines. A trial of hyposensitization therapy with autologous semen was successful. A trial of non-steroidal anti-inflammatory medication helped 1 patient described in a single case report, but failed to successfully treat other patients. POIS is a rare condition that is underdiagnosed and under-reported. Further studies are warranted to investigate the prevalence, pathophysiology, and treatment of this debilitating condition. Nguyen HMT, BalaA, Gabrielson AT, Hellstrom WJG. Post-Orgasmic Illness Syndrome: A Review. Sex Med Rev 2018;6:11-15.

Post-Orgasmic Illness Syndrome: Where Are We?

Post-Orgasmic Illness Syndrome: Where Are We?

282 Flooding as A Treatment for Post Orgasmic Illness Syndrome

282 Flooding as A Treatment for Post Orgasmic Illness Syndrome

Post orgasmic illness syndrome (POIS)

Men with post orgasmic illness syndrome (POIS) become ill rather immediately after ejaculation, whether spontaneously at night, during sexual intercourse or masturbation. Two subtypes are distinguished: primary and secondary POIS. It also occurs before or after a man has been sterilized. POIS is an invalidating most probably auto-immune disease leading to much distress in males and their partners. It is characterized by five criteria. Its symptoms are described by seven clusters. However, the manifestation of these symptoms varies from one male to the other but is relatively constant in the person himself. Among men the symptoms vary in intensity, durations and sort of symptoms. POIS is a chronic disorder that manifests itself in POIS “attacks” that occur within a few minutes to a few hours after ejaculation, and disappear spontaneously after 3 to 7 days. POIS is not associated with increased total serum IgE concentrations. On the contrary, there are indications that POIS is triggered by specific cytokines that are released by an auto-immune reaction to the man’s seminal fluid. Indirect clinical evidence suggests that the antigen (Ag) triggering the POIS systemic reaction is not bound to spermatozoa but to seminal fluid produced by prostatic tissue. In addition, POIS may also occur—although rarely—in females. In those cases, it is hypothesized that the Ag is associated with female prostatic tissue around the vagina.

Contemporary Management of Disorders of Male Orgasm and Ejaculation

Ejaculatory disorders lie along a conceptual continuum with premature ejaculation anchoring one end, normal ejaculation in the center, and difficulties with delayed or anejaculation at the opposite end. Retrograde ejaculation, painful ejaculation, and postorgasmic illness syndrome can occur at any point on the continuum. This manuscript defines the ejaculatory dysfunctions, reviews the anatomy and physiology of orgasm and ejaculation, and summarizes the pharmacological, psychological, and combined treatment approaches to ejaculatory dysfunctions.

Post-orgasmic illness syndrome: a case report

Post orgasmic illness syndrome (POIS) is a newly described syndrome. Manifestations of this syndrome may be physical, cognitive or both. Many theories have been proposed to explain the causes of this syndrome including allergy to seminal components, allergy to unknown proteins released during ejaculation or a psychosomatic etiology. We present a case of POIS with a manifestation of atopy that may be consistent with the allergy hypothesis.

AS01-04 - Post orgasmic illness syndrome: indications for an auto-immune pathogenesis

Post-orgasmic unwell being denoted as postorgasmic illness syndrome (POIS) was for the first time reported by Waldinger and Schweitzer in 2002 [1]. Recently, Waldinger et al. investigated 45 Caucasian males with complaints of POIS and categorized their symptoms in 5 preliminary criteria [2,3]. POIS is characterized by local mucosal manifestations (nasal congestion, itching eyes), and systemic features (flu-like syndrome with feverishness, muscle tension, exhaustion, foggy head, concentration difficulties, and mood irritability), occurring within 30–60 minutes after ejaculation. The symptoms always starts off after ejaculation, often reaching its peak severity at the second day and gradually diminishes within 1–7 days [3]. Affected males usually try to avoid ejaculating by planning intercourse or by abstaining from sexual activity. Waldinger et al. showed that 88% of the males had a positive intracutaneous (IC) skin-prick test for autologous semen and postulated that POIS is an expression of an auto-immune process. Support for this hypothesis comes from positive effects of hyposensitization treatment with diluted autologous semen in two men with POIS.